63 related articles for article (PubMed ID: 19317067)
1. [Effects of platelet and fibrinogen on progressive ovarian cancer].
Li CY; Wu M; Yuan JY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Feb; 31(1):81-3. PubMed ID: 19317067
[TBL] [Abstract][Full Text] [Related]
2. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
Petignat P; Vajda D; Obrist R
Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
[TBL] [Abstract][Full Text] [Related]
3. Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer.
Bozkurt N; Yuce K; Basaran M; Kose F; Ayhan A
Obstet Gynecol; 2004 Jan; 103(1):82-5. PubMed ID: 14704249
[TBL] [Abstract][Full Text] [Related]
4. Platelet Count After Chemotherapy is a Predictor for Outcome for Ovarian Cancer Patients.
Eggemann H; Ehricke J; Ignatov T; Fettke F; Semczuk A; Costa SD; Ignatov A
Cancer Invest; 2015 May; 33(5):193-6. PubMed ID: 25831456
[TBL] [Abstract][Full Text] [Related]
5. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
6. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumors that were treated by laparotomy.
Vandenput I; Amant F; Vergote I
Gynecol Oncol; 2005 Sep; 98(3):523; author reply 524-5. PubMed ID: 16054202
[No Abstract] [Full Text] [Related]
8. Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second-line chemotherapy.
Nather A; Mayerhofer K; Grimm C; Hefler L; Leodolter S; Obermair A; Joura EA
Anticancer Res; 2003; 23(3C):2991-4. PubMed ID: 12926151
[TBL] [Abstract][Full Text] [Related]
9. Immune thrombocytopenia associated with solid cancer.
Shimada T; Saito T; Choi I; Yamaguchi S; Shimamoto K; Ariyoshi K; Okadome M
J Obstet Gynaecol Res; 2015 Sep; 41(9):1495-8. PubMed ID: 26082063
[TBL] [Abstract][Full Text] [Related]
10. CA-125 level preoperative assessment in early and advanced ovarian carcinoma.
Raspollini MR
Gynecol Oncol; 2007 Nov; 107(2):356-7; author reply 357-8. PubMed ID: 17716712
[No Abstract] [Full Text] [Related]
11. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
[TBL] [Abstract][Full Text] [Related]
12. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
13. [Mucinous carcinoma-associated antigen (MCA) in ovarian cancer].
Hanzal E; Kölbl H; Gitsch G; Bieglmayer C
Gynakol Rundsch; 1990; 30 Suppl 1():68-70. PubMed ID: 2079303
[No Abstract] [Full Text] [Related]
14. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
[TBL] [Abstract][Full Text] [Related]
16. Metastatic ovarian serous carcinoma presenting as inflammatory breast cancer: a case report.
Gingell D; Samuel A; Haynik D; McBee W; Kelley J; Zorn K; Bhargava R
Int J Gynecol Pathol; 2010 May; 29(3):243-7. PubMed ID: 20407323
[TBL] [Abstract][Full Text] [Related]
17. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
18. A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer.
Mysona D; Pyrzak A; Purohit S; Zhi W; Sharma A; Tran L; Tran P; Bai S; Rungruang B; Ghamande S; She JX
Gynecol Oncol; 2019 Mar; 152(3):574-580. PubMed ID: 30578005
[TBL] [Abstract][Full Text] [Related]
19. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma.
Tate S; Hirai Y; Takeshima N; Hasumi K
Gynecol Oncol; 2005 Jan; 96(1):143-9. PubMed ID: 15589593
[TBL] [Abstract][Full Text] [Related]
20. Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern.
Laurent I; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
Ann Surg Oncol; 2008 Dec; 15(12):3561-6. PubMed ID: 18820973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]